Professor Kutner received his Ph.D. in chemistry from the Chemistry Department of the University of Warsaw and his D.Sc. (habilitation) from the Pharmacy Department of the Medical University of Warsaw, titular professor in pharmaceutical sciences. He works for the Pharmaceutical Research Institute since 1976. He is the author of the new convergent strategy of the synthesis of vitamin D metabolites and analogs and co-author of the new convergent strategy of synthesis of analogs of prostaglandin F2alfa. The strategies, based on new advanced synthons, were implemented at the Institute with a substantial contribution from the synthetic, analytical and manufacturing teams. The strategies allow for economic manufacturing at the Institute of vitamin D metabolites and analogs and of antiglaucoma prostaglandins for the European pharmaceutical market. He conceived synthetic retiferols, structurally related to both, vitamin D and vitamin A, as a new class of antipropliferating agents. He also designed a number of vitamin D analogs of anticancer activity in vivo in a therapy combined with cytostatics and tyrosine kinase inhibitors. At present he is involved in directing research and development in drug development programs at the Institute within the national Operational Programme of Innovative Economy and Technological Initiative of the National Center of Research and Development. He is a co-author of over 60 original publications and over 50 patents, both national and international. He is giving a monographic lecture Strategies of pharmaceutical syntheses for the four-grade students at the Chemistry Department, University of Warsaw, since 2006.
Publications in medicinal chemistry indexed in Pubmed
 Publications, complete list
|
